Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel.

A system of nanoparticles of mixed lipid monolayer shell and biodegradable polymer core was developed for targeted delivery of anticancer drugs with Docetaxel as a model drug, which provide targeting versatility with a quantitative control of the targeting effect by adjusting the lipid component ratio of the mixed lipid monolayer, and combine the advantages and avoid disadvantages of polymeric nanoparticles and liposomes in drug delivery. X-ray photoelectron spectroscopy (XPS) confirmed the coating of the mixed lipid monolayer on the polymeric core. Fluorescent microscopy proved the targeting efficacy of the folic acid conjugated on the mixed lipid monolayer for the cancer cells of over expression of folate receptors. The folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core were proved to possess sustainable, controlled and targeted delivery of anticancer drugs with Docetaxel as a model drug, which may provide a drug delivery system of precise control of the targeting effect.

[1]  M Ferrari,et al.  The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. , 2007, Biomaterials.

[2]  S. Chien,et al.  Chemotherapeutic engineering : Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168h in vivo , 2007 .

[3]  Robert Langer,et al.  PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. , 2009, Biomaterials.

[4]  X. Wu,et al.  Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[5]  P. Low,et al.  Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. , 1995, Biochimica et biophysica acta.

[6]  Robert Langer,et al.  Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.

[7]  X. Wu,et al.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Chee Wee Gan,et al.  Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. , 2009, Biomaterials.

[9]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[10]  X. Wu,et al.  In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  Shuming Nie,et al.  Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery , 2006, Molecular Cancer Therapeutics.

[12]  Robert J. Lee,et al.  A folate receptor-targeted liposomal formulation for paclitaxel. , 2006, International journal of pharmaceutics.

[13]  P. Low,et al.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  You Han Bae,et al.  Polymeric micelle for tumor pH and folate-mediated targeting. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[15]  S. Benita,et al.  Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[16]  S. Feng,et al.  In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. , 2007, Biomaterials.

[17]  X. Wu,et al.  A Mechanistic Study of Enhanced Doxorubicin Uptake and Retention in Multidrug Resistant Breast Cancer Cells Using a Polymer-Lipid Hybrid Nanoparticle System , 2006, Journal of Pharmacology and Experimental Therapeutics.

[18]  Jie Pan,et al.  Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers. , 2009, Biomaterials.

[19]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[20]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[21]  S. Feng,et al.  Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[22]  J. Verweij,et al.  Alternative drug formulations of docetaxel: a review. , 2007, Anti-cancer drugs.

[23]  T. Yang,et al.  Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells , 2007, Pharmaceutical Research.

[24]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[25]  Taiji Kato,et al.  A cellular uptake of cis-platinum-encapsulating liposome through endocytosis by human neuroblastoma cell , 1991, Neurochemistry International.

[26]  Tae Gwan Park,et al.  Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[27]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[28]  A. Goyal,et al.  Solid Lipid Nanoparticles (SLNs) as a Rising Tool in Drug Delivery Science: One Step Up in Nanotechnology , 2008 .

[29]  Laurent David,et al.  Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. , 2007, Biomacromolecules.

[30]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Xu Wang,et al.  Application of Nanotechnology in Cancer Therapy and Imaging , 2008, CA: a cancer journal for clinicians.

[32]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[33]  Si-Shen Feng,et al.  The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. , 2006, Biomaterials.

[34]  Y. Maitani,et al.  Effect of Polyethylene Glycol Linker Chain Length of Folate-Linked Microemulsions Loading Aclacinomycin A on Targeting Ability and Antitumor Effect In vitro and In vivo , 2005, Clinical Cancer Research.

[35]  Y. Sugiyama,et al.  Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Jianjun Cheng,et al.  Anticancer Polymeric Nanomedicines , 2007 .

[37]  E. Moase,et al.  Therapeutic opportunities for targeted liposomal drug delivery , 1996 .

[38]  Ignacio De Miguel,et al.  Proofs of the Structure of Lipid Coated Nanoparticles (SMBV™) Used as Drug Carriers , 2000, Pharmaceutical Research.

[39]  Tae-You Kim,et al.  Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.

[40]  R. Langer,et al.  Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.